AffiliationDepartment of Medical Oncology, Christie Hospital, Withington, Manchester, U.K.
MetadataShow full item record
AbstractFive glycoprotein growth factors capable of stimulating the proliferation and differentiation of haemopoietic progenitor cells in vitro have been identified and sequenced over the past ten years. Recombinant DNA technology has recently enabled the production of sufficient amounts of these agents for preclinical testing. Erythropoietin (EPO), granulocyte-macrophage colony-stimulating factor (GM-CSF), and granulocyte colony-stimulating factor (G-CSF) have already entered clinical studies in humans. Interleukin-3 (IL-3) and macrophage colony-stimulating factor (M-CSF) should soon be available for use in humans. EPO corrects the anaemia of end stage renal failure, improving the quality of life for such patients and preventing the need for red cell transfusions. At high dose it increases platelet production in vitro and in vivo and may be of value in humans to prevent the thrombocytopaenia associated with chemotherapy. G-CSF and GM-CSF have been used in several clinical studies. Administration of both growth factors results in a leucocytosis, G-CSF predominantly increasing neutrophil production and GM-CSF increasing production of neutrophils, eosinophils and monocytes. The optimal administration of these agents is via continuous intravenous infusion or daily subcutaneous injections at doses of 3-10 micrograms/kg/24 h. GM-CSF has shown promising results in patients with AIDS and the myelodysplastic syndrome and both G-CSF and GM-CSF have reduced the duration of neutropaenia and incidence of infection associated with chemotherapy. These agents may allow an escalation of the dose-intensity of chemotherapy in the future and thereby, hopefully, increase the response rate and survival for patients with a variety of neoplasms. Several other potential roles for these haemopoietic growth factors are discussed.
CitationClinical trials with haemopoietic growth factors. 1989, 1 (1):1-12 Prog. Growth Factor Res.
JournalProgress in Growth Factor Research
- Myelodysplastic syndromes: a guide to treatment with epoetin and colony-stimulating factors.
- Authors: Geissler RG, Ganser A
- Issue date: 1998 Aug
- Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
- Authors: Laughlin MJ, Kirkpatrick G, Sabiston N, Peters W, Kurtzberg J
- Issue date: 1993 Dec
- The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
- Authors: Greenberg PL, Negrin R, Nagler A
- Issue date: 1990
- Clinical toxicity of cytokines used as haemopoietic growth factors.
- Authors: Vial T, Descotes J
- Issue date: 1995 Dec
- Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
- Authors: Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, Bodenizza C, Perla G, Carotenuto M
- Issue date: 2001 Jan